Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) for the event date of October 8, 2020, with a report date of October 14, 2020. The filing addresses a notice of delisting or failure to satisfy a continued listing rule regarding the Company's common stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed is the stock price performance triggering the listing deficiency: the closing bid price of the Company's securities was less than $1.00 per share for the previous 30 consecutive business days.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq on October 8, 2020, stating non-compliance with Listing Rule 5550(a)(2) due to the low minimum bid price. This places the Company in a 180-day compliance period ending April 6, 2021, to regain compliance.
Outlook, Risks, and Management Commentary
- Compliance Path: To regain compliance, the stock must close at $1.00 or more for 10 consecutive business days within the 180-day window.
- Reverse Stock Split: The Company has stockholder approval (from May 21, 2020) to effect a reverse stock split at a ratio between 1-for-3 and 1-for-20, exercisable by May 20, 2021. Management intends to consider this option if necessary.
- Risks: Failure to regain compliance could lead to delisting, which may impair liquidity, reduce market price, and materially adversely affect access to capital markets.
- Delisting Triggers: Delisting will occur if compliance is not met within the allotted period or if the closing bid price falls to $0.10 or less for ten consecutive trading days during the compliance period.
Investor Verification Checklist
- Verify the current trading price of MGEN to assess proximity to the $1.00 compliance threshold.
- Monitor for any press releases or filings announcing the implementation of a reverse stock split.
- Check for any subsequent correspondence from Nasdaq regarding the Company's compliance status or potential extensions.
- Review the Company's cash position in other filings (e.g., 10-Q or 10-K) to understand its ability to fund operations if capital access is restricted.